Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text
DOI
 |
Open Access Hybrid |
|
as soon as is submitted to ZB.
GLP-1-Mimetika – wegweisend zur Behandlung von Diabetes und Adipositas.
GLP-1 mimetics - pioneering for the treatment of diabetes and obesity.
BioSpektrum 29, 137-139 (2023)
Most obese patients would benefit from 5–10 % of weight loss but fail
when using non-surgical approaches. The recent development of two
anti-obesity drugs may change that therapeutic gap. Patients receiving
long-acting glucagon-like peptide 1 (GLP1) agonist semaglutide achieve
weight loss above 10 %. With tirzepatide, a co-agonist for GLP-1 and the
gastric inhibitory polypeptide (GIP) receptor, more than 50 % of the
patients even lose above 20 %, which rivals the efficacy of surgical
interventions.
Impact Factor
Scopus SNIP
Altmetric
0.000
0.007
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Language
german
Publication Year
2023
HGF-reported in Year
2023
ISSN (print) / ISBN
0947-0867
e-ISSN
1868-6249
Journal
BioSpektrum
Quellenangaben
Volume: 29,
Issue: 2,
Pages: 137-139
Publisher
Springer
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes and Obesity (IDO)
POF-Topic(s)
90000 - German Center for Diabetes Research
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-501900-221
Scopus ID
85153393860
Erfassungsdatum
2023-11-30